MedPath

Teva Pharma B.V.

🇳🇱Netherlands
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.tevapharm.com

Clinical Trials

18

Active:0
Completed:15

Trial Phases

3 Phases

Phase 2:4
Phase 3:7
Phase 4:1

Drug Approvals

38

EMA:38

Drug Approvals

Seffalair Spiromax

Authorization Status
Authorised
Approval Date
Mar 26, 2021
EMA

BroPair Spiromax

Authorization Status
Authorised
Approval Date
Mar 26, 2021
EMA

GoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.)

Authorization Status
Authorised
Approval Date
Apr 3, 2020
EMA

Tacforius

Authorization Status
Authorised
Approval Date
Dec 8, 2017
EMA

Tacforius

Authorization Status
Authorised
Approval Date
Dec 8, 2017
EMA

Cinqaero

Authorization Status
Authorised
Approval Date
Aug 15, 2016
EMA

Clopidogrel ratiopharm

Authorization Status
Authorised
Approval Date
Feb 18, 2015
EMA

Rasagiline ratiopharm

Authorization Status
Authorised
Approval Date
Jan 12, 2015
EMA

DuoResp Spiromax

Authorization Status
Authorised
Approval Date
Apr 28, 2014
EMA

BiResp Spiromax

Authorization Status
Authorised
Approval Date
Apr 28, 2014
EMA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

Clinical Trials

Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials

Phase 3
7 (58.3%)
Phase 2
4 (33.3%)
Phase 4
1 (8.3%)

Prospective Observational Study in Patients With Metastatic Breast Cancer Treated With Anthracyclines

Completed
Conditions
Metastatic Breast Cancer
First Posted Date
2012-03-16
Last Posted Date
2016-04-25
Lead Sponsor
Teva Pharma
Target Recruit Count
60
Registration Number
NCT01555944
Locations
🇧🇪

ZNA Middelheim, Antwerp, Belgium

🇧🇪

Cliniques du Sud Lux - St Joseph, Arlon, Belgium

🇧🇪

Imelda, Bonheiden, Belgium

and more 21 locations

News

No news found
© Copyright 2025. All Rights Reserved by MedPath